Research Study

Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes
Principal Investigator 
Thomas G. Elliott

Overview

Body Locations and Systems 
Diabetes - Type 1
Disorders and Conditions 
ClinicalTrials.gov# 
NCT02117765
Status 
Recruiting
Study Start/End 
Jul 2, 2014 to Jan 9, 2018
Locations 
Diamond Health Care Centre
Name/Title 
Marla Inducil, Research Associate
Phone 
604-628-7253
Email Address 
marla.inducil@vch.ca
Purpose of Study 

In type 1 diabetes (T1D), immune defense cells in the body attack and destroy insulin-producing beta cells leaving affected people with a lifelong need for daily insulin injections. Even with insulin injections, blood glucose (sugar) control is imperfect and leads to many health complications and a shortened life span. This is a pilot clinical trial to test the safety of a drug, ustekinumab, in 20 adult subjects with recent-onset T1D. Ustekinumab is currently licensed for use in psoriasis where it has proven to be both highly effective and safe and so the investigators hope to see a similar effect in T1D. This trial will also be used to determine the best dosage and frequency of the drug to be given to people with T1D to help design future studies on the drug's effectiveness. The investigators hope that if the drug can block immune cells soon after the development of diabetes, any remaining insulin-producing cells may be protected, and regenerate, thus producing more insulin so that individuals may be insulin free, or require less insulin.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.